The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Regulation of osteoclastic activity is critical for understanding bone loss associated with the postmenopausal period. In vitro and animal studies have revealed the role of OPG as a decoy receptor that neutralizes the effect of RANKL on the differentiation and activation of osteoclasts. However, the role of the OPG-RANKL system in postmenopausal osteoporosis is controversial. Thus, the aim of this study was to investigate the relationship among circulating levels of OPG, RANKL, bone turnover markers (BTM), bone mineral density (BMD) and vertebral fractures in postmenopausal women. We determined anthropometric parameters, circulating OPG and RANKL, BTM, estradiol, BMD by dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN), and pre-existing vertebral fractures in 206 ambulatory postmenopausal women of a mean age of 62 years (SD 7). Circulating OPG was significantly related to age (r =0.158; P =0.023), years since menopause (r =0.167; P =0.016) and BMD (LS Z-score: r =0.240; P =0.001, FN Z-score: r =0.156; P =0.025). Over half of the women had undetectable RANKL (n =113; 54.9%). There were no significant differences in clinical variables, BTM or BMD among women with detectable vs. undetectable RANKL. OPG was found to be independently associated with osteoporosis (OR: 2.9, 1.4-5.9) and prevalent vertebral fractures (OR: 2.5, 1.2-5.4). We conclude that serum OPG levels are independently associated with bone mass and prevalent vertebral fractures in postmenopausal women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“However, in one of the studies over half of the women (54.9%) had concentrations of RANKL that were undetectable (379), and in the other study 40% of samples were below the detection limit of the assay (385).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Serum RANKL levels have also been investigated in postmenopausal women and reported not to be associated with menopausal status or BMD (379, 385) but to be associated with nontraumatic fracture (385).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [379]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 1×
“Moreover, OPG administration protects against the decrease in bone mass that occurs in the ovariectomized/estrogen-deficient rat model of postmenopausal osteoporosis [8].”
Background(1994) · PubMed · Cited by 4,959
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Sex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846 · cited 1×
“It appears likely that estrogens inhibit bone resorption by inducing small but cumulative changes in multiple estrogen-dependent regulatory factors [28].”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · cited 1×
“In prior in vitro and animal studies, OPG has been shown to reduce or prevent increased bone resorption [2, 3].”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173 · cited 2×
“In addition, OPG and RANKL have been implicated in the pathogenesis of osteoporosis and other metabolic bone diseases [1].”
BackgroundRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 3×
“[9], which is likely to be the result of the actions of other cytokines.”
BackgroundInfluentialBekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771 · cited 2×
“In prior in vitro and animal studies, OPG has been shown to reduce or prevent increased bone resorption [2, 3]. Both OPG [4] and RANKL antibody [ 5 ] administration to humans have been demonstrated to cause marked decreases in bone resorption.”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 3×
“Recent pharmacological studies have shown that estrogen increases osteoblast production of OPG [6] and inhibits RANKLmediated osteoclastogenesis [7] in in-vitro and rodent models.”
BackgroundBrowner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 2×
“[12] observed a significant negative correlation between OC and OPG.”
Background
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Dimorphic effects of Notch signaling in bone homeostasis
Engin, F., Yao, Z., Yang, T., Zhou, G., Bertin, T., Jiang, M. M., Chen, Y., Wang, L., Zheng, H., Sutton, R. E., et al. (2008) · Nature Medicine · doi:10.1038/nm1712 · Cited by 413
“Moreover, it raises the question of whether loss of Notch signaling contributes to age-related osteoporosis, as this type of osteoporosis is associated with increased resorption over bone formatio”
BackgroundTanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
Goëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“In several other cohorts, no correlation was found between OPG and bone resorption markers in women whatever their menopause status was.(36,40) In contrast, a positive relationship between bone turnover markers and OPG was found in postmenopausal women(41) and in both men and women in a study by Indridason et al.”
The link between osteoporosis and cardiovascular disease.
Farhat, G. N., & Cauley, J. A. (2008) · PubMed · Cited by 194
Metadata
- Authors
- Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M.
- Affiliations
- Universidad de Granada (ES)
- University Hospital Zurich (CH)
- Venue
- Osteoporosis International
- Published
- 2005-02-12
- Volume
- 16
- Issue
- 11
- Pages
- 1368-1374
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2146240002
- Cited by
- 98
- References
- 31
- Citations by year
- 2025: 1 · 2024: 3 · 2022: 5 · 2021: 1 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- osteoprotegerin, RANKL, postmenopausal osteoporosis, vertebral fractures, bone mineral density, bone turnover markers, osteoclast activity, menopause, serum biomarkers, postmenopausal women
- MeSH terms
- Tartrate-Resistant Acid Phosphatase, Acid Phosphatase, Aged, Alkaline Phosphatase, Carrier Proteins, Estradiol, Female, Femur Neck, Glycoproteins, Humans, Isoenzymes, Lumbar Vertebrae, Membrane Glycoproteins, Middle Aged, Prospective Studies, Biomarkers, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. https://app.cochat.ai/papers/10.1007/s00198-005-1844-1
- The paper
- Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005). The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporosis International. https://doi.org/10.1007/s00198-005-1844-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.